Pancreatic Cancer Research

ResearcherLeiden University Medical CenterActive in the last 2 years

Carmen Guillén‐Ponce

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3594-1084; OpenAlex author ID A5050960262. Sources: ClinicalTrials.gov.

Their work

Papers
24 (first author 1, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
120
Papers, trials and grants by year

2015: 2 papers · 2016: 3 papers · 2017: 5 papers · 2018: 2 papers · 2019: 2 papers · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper, 1 trial · 2024: 1 paper · 2025: 3 papers · 2026: 3 papers

Papers 24

  1. Prognostic modeling of overall survival in metastatic pancreatic cancer: an inflammation-based tool validated in PANTHEIA-SEOM cohort. Co-author DOI 10.1007/s12094-026-04554-8↗
  2. Systemic inflammation response index (SIRI) predicts outcomes and chemotherapy benefit in metastatic pancreatic cancer: A study by the PANTHEIA- SEOM group. Co-author DOI 10.1016/j.pan.2026.08.008↗
  3. Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial. Co-author DOI 10.1038/s41591-026-04705-y↗
  4. Utility of endoscopic ultrasound-guided fine needle aspiration for genetic analysis in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.hpb.2024.11.009↗
  5. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  6. A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial. Co-author DOI 10.1158/1078-0432.ccr-23-4026↗
  7. Nab-Paclitaxel plus Gemcitabine and FOLFOX in Metastatic Pancreatic Cancer. Co-author DOI 10.1056/evidoa2300144↗
  8. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA. Co-author DOI 10.1186/s13073-023-01171-w↗
  9. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Tr… Co-author DOI 10.1158/1078-0432.ccr-21-0929↗
  10. Phase I/II trial of sequential treatment of nab-paclitaxel in combination with gemcitabine followed by modified FOLFOX chemotherapy in patients with untreated … Co-author DOI 10.1016/j.ejca.2020.07.035↗
  11. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: Results of the PANOVA phase 2 study. Co-author DOI 10.1016/j.pan.2018.10.004↗
  12. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cance… Co-author DOI 10.1200/jco.18.00089↗
  13. Prognostic factors for survival with nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: the ANICE-PaC study. Co-author DOI 10.1186/s12885-018-5101-3↗
  14. Integrative multi-platform meta-analysis of gene expression profiles in pancreatic ductal adenocarcinoma patients for identifying novel diagnostic biomarkers. Co-author DOI 10.1371/journal.pone.0194844↗
  15. A phase II study of antibody-drug conjugate, TAK-264 (MLN0264) in previously treated patients with advanced or metastatic pancreatic adenocarcinoma expressing … Co-author DOI 10.1007/s10637-017-0473-9↗
  16. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Co-author DOI 10.1007/s12094-016-1594-x↗
  17. Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety … Co-author DOI 10.1016/j.ejca.2016.12.032↗
  18. A systems approach identifies time-dependent associations of multimorbidities with pancreatic cancer risk. Co-author DOI 10.1093/annonc/mdx167↗
  19. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. Co-author DOI 10.1136/gutjnl-2015-310442↗
  20. Identification of gene expression profiling associated with erlotinib-related skin toxicity in pancreatic adenocarcinoma patients. Co-author DOI 10.1016/j.taap.2016.10.003↗
  21. Refinement of screening for familial pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-311098↗
  22. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. Co-author DOI 10.1200/jco.2015.64.0730↗
  23. PanGen-Fam: Spanish registry of hereditary pancreatic cancer. First author DOI 10.1016/j.ejca.2015.07.004↗
  24. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine panc… Last author DOI 10.1186/s12885-015-1779-7↗

Trials 1

  1. Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer Principal investigator NCT05673811↗

Closest collaborators

The 25 strongest of 120 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Javier Gallego-Plazas · 9 shared papers, 2016–2026 · strength 1.02
  2. Roberto Pazo-Cid · 8 shared papers, 2017–2026 · strength 0.95
  3. Teresa Mercade Macarulla · 7 shared papers, 2017–2026 · strength 0.80
  4. Manuel M. Hidalgo · 6 shared papers, 2017–2026 · strength 0.77
  5. Rocio García‐Carbonero · 4 shared papers, 2023–2026 · strength 0.72
  6. Alfredo Carrato · 9 shared papers, 2015–2024 · strength 0.57
  7. Alberto Carmona‐Bayonas · 4 shared papers, 2017–2026 · strength 0.55
  8. Jaime Feliú · 4 shared papers, 2017–2025 · strength 0.49
  9. Ángela Lamarca · 2 shared papers, 2026 · strength 0.45
  10. Vilma Pacheco-Barcía · 2 shared papers, 2026 · strength 0.45
  11. Elena Brozos-Vázquez · 2 shared papers, 2026 · strength 0.45
  12. Enrique Aranda · 5 shared papers, 2016–2024 · strength 0.45
  13. Eva Martínez de Castro · 1 shared paper, 1 shared trial, 2023–2026 · strength 0.43
  14. Fernando Rivera · 4 shared papers, 2017–2024 · strength 0.41
  15. Manuel Benavides · 5 shared papers, 2016–2020 · strength 0.40
  16. Andrés Jesús Muñoz Martín · 3 shared papers, 2018–2026 · strength 0.36
  17. Enrique Vázquez-Sequeiros · 4 shared papers, 2015–2025 · strength 0.34
  18. Francesca Sarno · 2 shared papers, 2023–2025 · strength 0.34
  19. Bruno Bockorny · 2 shared papers, 2021–2025 · strength 0.29
  20. Ismael Ghanem · 1 shared paper, 2026 · strength 0.23
  21. Luis Cabezón‐Gutiérrez · 1 shared paper, 2026 · strength 0.22
  22. Mireya Cazorla · 1 shared trial, 2023 · strength 0.22
  23. Andrés Muñoz · 1 shared trial, 2023 · strength 0.22
  24. Teresa Macarulla · 1 shared trial, 2023 · strength 0.22
  25. Roberto Pazo · 1 shared trial, 2023 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.